RBC Says Tekmira Pharmaceuticals Corporation (TKMR) Hype Missing The PointMark Melin
As the roller coaster ride that is the Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) stock continues, the Royal Bank of Canada (NYSE:RY) (TSE:RY) is out with a new report that seems to suggest investors are missing the point.
Tekmira's Hepatitis B cure is the real value
The RBC research report shouts the headline that while the Ebola scare, and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)’s cure for the health epidemic, is in the headlines, it is the firm’s Hepatitis B cure that . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.